Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseasesReportar como inadecuado




Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

International Nano Letters

, Volume 7, Issue 2, pp 91–122

First Online: 28 April 2017Received: 13 December 2016Accepted: 24 April 2017DOI: 10.1007-s40089-017-0208-0

Cite this article as: Chowdhury, A., Kunjiappan, S., Panneerselvam, T. et al. Int Nano Lett 2017 7: 91. doi:10.1007-s40089-017-0208-0

Abstract

Degenerative diseases are results of deterioration of cells and tissues with aging either by unhealthy lifestyle or normal senescence. The degenerative disease likely affects central nervous system and cardiovascular system to a great extent. Certain medications and therapies have emerged for the treatment of degenerative diseases, but in most cases bearing with poor solubility, lower bioavailability, drug resistance, and incapability to cross the blood–brain barrier BBB. Hence, it has to be overcome with conventional treatment system; in this connection, nanotechnology has gained a great deal of interest in recent years. Moreover, nanotechnology and nanocarrier-based approach drug delivery system could revolutionize the treatment of degenerative diseases by faster absorption of drug, targeted interaction at specific site, and its release in a controlled manner into human body with minimal side effects. The core objective of this review is to customize and formulate therapeutically active molecules with specific site of action and without affecting other organs and tissues to obtain effective result in the improvement of quality of health. In addition, the review provides a concise insight into the recent developments and applications of nanotech and nanocarrier-based drug delivery for the treatment of various degenerative diseases.

KeywordsDegenerative diseases Nanotechnology Nanocarrier Biocompatibility Drug delivery Drug resistance Drug development Bioavailability Blood–brain barrier 



Autor: Anindita Chowdhury - Selvaraj Kunjiappan - Theivendren Panneerselvam - Balasubramanian Somasundaram - Chiranjib Bhattacharjee

Fuente: https://link.springer.com/







Documentos relacionados